Earnings Releases·Nov 12, 2026, 4:17 PM ET

Electra Therapeutics — Third Quarter 2026 Earnings Summary

Q3 2026 net loss widened to $23.9 million from $18.1 million in the prior year period, driven by a 16% increase in R&D expenses ($17.3M vs. $14.9M) and a 333% surge in G&A expenses ($7.8M vs. $1.8M); cash and marketable securities reached $402.5 million following $320.0 million in net IPO proceeds.
The company projects its current cash position will fund operations through 2029, with key 2027 milestones including ELA822 healthy volunteer data (H1 2027), ipsoprubart T/NK malignancy data (H2 2027), and completion of the SURPASS sHLH enrollment (H2 2027).
Clinical progress for lead candidate ipsoprubart (ELA026) showed 100% overall survival and 100% overall response rate in a Phase 1b sHLH trial, while ELA822 Phase 1 healthy volunteer trials commenced in September 2026.
Management transitioned from private to public status with 6.89 million common shares outstanding, citing the September 2026 IPO as a strategic enabler to leverage their first-mover advantage in SIRP-targeted precision immune cell depletion.